Condition
Diabetes Mellitus, Type 1
Locations
Germany
Start date
12/11/2024
Identifiers
Trial ID
NN1644-7794,
NCT number NCT06685185,
Eudract number Not Available
NCT number NCT06685185,
Eudract number Not Available
Summary
This study will look into testing a new medicine called NNC0363-1063 which may be used to treat people with diabetes. The study consists of three parts: Part 1 is a single ascending dose (SAD) study that comprises two subtypes: Part 1A conducted in healthy participants and Part 1B conducted in participants with type 1 diabetes (T1D). This study part will last for about 1½ to 5½ weeks. Part 2 is a proof-of-principle (PoP) study part conducted in participants with T1D and will last for about 2½ to 6½ weeks. Part 3 is a multiple ascending dose (MAD) study part conducted in participants with T1D and will last for 3½ to 8½ weeks.
Trial Overview:
Treatment
DRUG: NNC0363-1063
DRUG: Placebo
DRUG: Insulin degludec
Study type
INTERVENTIONAL
Trial duration
Nov 12 2024 - Jul 24 2025
Participants
154
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 64 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.